ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc ...

ImmunityBio ASCO ANKTIVA Data Reframes Lung And Bladder Cancer Outlook

ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The ...

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one ...

Ebola: Virus can persist for hundreds of days in people infected, doctor says | CUOMO

Shiong, executive chairman of ImmunityBio, joins “CUOMO” to discuss the latest developments in the Ebola outbreak. The Ebola ...

Ebola virus can linger in body for hundreds of days, doctor warns

Dr. Patrick Soon-Shiong, executive chairman of ImmunityBio, said research from Washington State University shows the virus ...

Analysts Offer Insights on Healthcare Companies: ImmunityBio (IBRX), Abivax SA Sponsored ADR (ABVX) and Precigen (PGEN)

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.
Business Insider

The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, ...
MedPage Today on MSN

Drug combo for lung cancer beats pembrolizumab in first-line trial

Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expres ...